These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443 [TBL] [Abstract][Full Text] [Related]
6. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation. Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R Respiration; 2016; 91(1):9-17. PubMed ID: 26492415 [TBL] [Abstract][Full Text] [Related]
7. Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases. Alves JL; Gavilanes F; Jardim C; Fernandes CJCDS; Morinaga LTK; Dias B; Hoette S; Humbert M; Souza R Chest; 2015 Feb; 147(2):495-501. PubMed ID: 25317567 [TBL] [Abstract][Full Text] [Related]
8. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD; Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414 [TBL] [Abstract][Full Text] [Related]
9. Contrasting cardiopulmonary responses to incremental exercise in patients with schistosomiasis-associated and idiopathic pulmonary arterial hypertension with similar resting hemodynamic impairment. Valois FM; Nery LE; Ramos RP; Ferreira EV; Silva CC; Neder JA; Ota-Arakaki JS PLoS One; 2014; 9(2):e87699. PubMed ID: 24498356 [TBL] [Abstract][Full Text] [Related]
10. Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study. Hay BR; Pugh ME; Robbins IM; Hemnes AR Chest; 2016 Mar; 149(3):660-6. PubMed ID: 26378379 [TBL] [Abstract][Full Text] [Related]
11. Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors. Sakao S; Tanabe N; Kasahara Y; Tatsumi K Intern Med; 2012; 51(19):2721-6. PubMed ID: 23037462 [TBL] [Abstract][Full Text] [Related]
12. Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. Knafl D; Gerges C; King CH; Humbert M; Bustinduy AL Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32024722 [TBL] [Abstract][Full Text] [Related]
13. Demographic and clinical characteristics of pulmonary arterial hypertension caused by schistosomiasis are indistinguishable from other etiologies. Mendes AA; Roncal CGP; Oliveira FRA; Albuquerque ES; Góes GHB; Piscoya ICV; Sobral Filho DC Rev Soc Bras Med Trop; 2020; 53():e20190418. PubMed ID: 32049203 [TBL] [Abstract][Full Text] [Related]
17. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension. Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360 [TBL] [Abstract][Full Text] [Related]
18. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636 [TBL] [Abstract][Full Text] [Related]
19. A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension. Woods PR; Taylor BJ; Frantz RP; Johnson BD Am J Cardiol; 2012 Apr; 109(7):1066-72. PubMed ID: 22245407 [TBL] [Abstract][Full Text] [Related]